RESUMO
Human IgM monoclonal antibody 16-88, derived from patients immunized with autologous colon carcinoma cells, was derivatized with two different cross-linkers, S-(2-thiopyridyl)-L-cysteine hydrazide (TPCH), which is carbohydrate-directed, and N-succinimidyl-3-(2- pyridyldithio)propionate (SPDP), which is amino group-directed. Two antibody functions, antigen binding and complement activation, were assayed upon derivatization with TPCH and SPDP. TPCH allowed for extensive modification (up to 17 TPCH molecules per antibody) without impairment of antigen binding activity, while this function was significantly compromised upon derivatization with SPDP. Antibody molecules derivatized with 16 SPDP residues showed almost complete loss of their antigen binding function. The complement activating ability of antibody 16-88 was significantly decreased after derivatization with TPCH or SPDP. In the case of SPDP derivatization, this decrease of the complement activating ability is predominantly a consequence of the impaired binding function. Upon conjugation of cobra venom factor (CVF), a nontoxic 137-kDa glycoprotein which is capable of activating the alternative pathway of complement, the antigen binding activity of SPDP-derivatized antibody was further compromised, whereas that of TPCH-derivatized antibody remained unaffected even after attachment of three or four CVF molecules per antibody. In both conjugates CVF retained good functional activity. CVF was slightly more active when attached to SPDP-derivatized antibody, suggesting a better accessibility of amino group-coupled CVF for its interaction with other complement proteins. These results indicate that carbohydrate-directed conjugation compromises the antibody function of complement activation, but allows for the generation of immunoconjugates with unimpaired antigen binding capability.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Ativação do Complemento/efeitos dos fármacos , Venenos Elapídicos , Hemólise/efeitos dos fármacos , Imunotoxinas , Animais , Anticorpos Monoclonais , Complexo Antígeno-Anticorpo , Sítios de Ligação , Neoplasias do Colo/imunologia , Reagentes de Ligações Cruzadas , Cisteína/análogos & derivados , Venenos Elapídicos/farmacologia , Eritrócitos/efeitos dos fármacos , Cobaias , Humanos , Imunoglobulina M , Imunotoxinas/farmacologia , Piridinas , SuccinimidasRESUMO
Tumor immunity developing as a response to an autologous colon-tumor/bacillus Calmette-Guérin (BCG) vaccine appears to be associated with induction of CD4+ helper T cells, implied by the observation that vaccine efficacy is associated with major histocompatibility complex class-II molecule expression on the vaccine tumor cells. Therefore, in an attempt to identify colon-tumor-associated antigens responsible for conferring immunity, we examined and compared the proliferative responses of peripheral-blood lymphocytes (PBL) from patients immunized with the autologous tumor/BCG vaccine to T-cell lines cloned expanded from colon-tumor-infiltrating lymphocytes to 5 antigens isolated on the basis of their reactivity by colon-tumor-reactive human monoclonal antibodies. Enzymatically dissociated colon tumors provided a source for establishment of cloned T-cell lines, tumor cell lines propagated in vitro or in vivo as nude-mouse xenografts and EBV-transformed B-cell lines used as antigen-presenting cells. Of 104 different T-cell lines tested, only 3 proliferated in response to CTAA 28A32-46K, and I to the CTAA28A32-32K antigen. In contrast, PBL from 64% of patients immunized with the autologous colon-tumor/BCG vaccine responded to the CTAA 28A32-32K antigen. This antigen is related to a family of calcium- and phospholipid-binding placental proteins termed annexins. Since proliferative responses developed to this antigen after vaccination in 64% of individuals, this antigen may be an important common colon-tumor-associated rejection antigen.
Assuntos
Antígenos de Neoplasias/análise , Vacina BCG/administração & dosagem , Neoplasias do Colo/imunologia , Antígenos HLA/análise , Linfócitos do Interstício Tumoral/imunologia , Animais , Anticorpos Monoclonais , Antígeno Carcinoembrionário/análise , Linhagem Celular Transformada , Rearranjo Gênico do Linfócito T , Glicoproteínas/análise , Humanos , Imunização , Imunoterapia , Linfócitos/imunologia , Camundongos , Camundongos Nus , Células Tumorais CultivadasRESUMO
A novel affinity system for a two-phase delivery of radionuclides to tumor cells has been developed. In the first phase, a nontoxic bivalent monoclonal antibody conjugated to an enzyme is targeted to the tumor cells. In the second phase, a radionuclide-derivatized enzyme inhibitor, specific for the enzyme conjugated to the antibody, is administered. The model system selected for this study is the recombinant human enzyme dihydrofolate reductase (rhDHFR) and its high-affinity competitive inhibitor methotrexate (MTX). MTX was labeled with a radionuclide by covalent attachment of diethylenetriaminepentaacetic acid (DTPA) complexed with 111In. Using the gamma-carboxyl residue of MTX for the attachment of DTPA, binding of the inhibitor to rhDHFR was not affected. The inhibitory activities of nonderivatized MTX and DTPA-MTX were indistinguishable. Human K562 erythroleukemia cells were used to evaluate under in vitro conditions the DHFR-MTX affinity system for the delivery of 111In-labeled DTPA-MTX to pretargeted alpha-transferrin receptor antibody-rhDHFR conjugates (alpha-TFR-DHFR). The data demonstrate that the delivery of 111In is dose dependent and highly specific. Under saturating conditions, binding of 111In-DTPA-MTX to alpha-TFR-DHFR-treated cells was 14-fold higher than to cells treated with nonconjugated alpha-TFR antibody. Further experiments indicated that the low level of nonspecific binding of 111In-DTPA-MTX was comparable to that of 111In-DTPA, known for its complete extracellular distribution and rapid clearance through the kidneys. Based on the data of this study, antibody-conjugated rhDHFR and radionuclide-labeled DTPA-MTX complexes provide components for an alternative radioimmunotherapeutic approach that can be expected to result in improved tumor tissue ratios of both the targeting moiety and the radionuclide-labeled derivative as compared to current approaches.
Assuntos
Imunotoxinas/metabolismo , Radioisótopos de Índio/administração & dosagem , Metotrexato/farmacocinética , Ácido Pentético/farmacocinética , Tetra-Hidrofolato Desidrogenase/metabolismo , Anticorpos Monoclonais/metabolismo , Anticorpos Monoclonais/uso terapêutico , Portadores de Fármacos , Antagonistas do Ácido Fólico , Humanos , Imunoglobulina G/metabolismo , Imunotoxinas/uso terapêutico , Cinética , Leucemia Eritroblástica Aguda/metabolismo , Leucemia Eritroblástica Aguda/radioterapia , Metotrexato/metabolismo , Ácido Pentético/metabolismo , Radioimunoterapia , Receptores da Transferrina/imunologiaRESUMO
Five different colon tumor-associated antigens (CTAA) were tested for their ability to induce an immune response in vivo and in vitro in ten colon carcinoma patients immunized with an irradiated autologous tumor cell/Bacillus Calmette-Guérin vaccine (active specific immunization) after resection of the primary tumor. The CTAA were defined by two different human monoclonal antibodies (MCA 1688 and MCA 28A32) derived by immortalization of peripheral blood B-lymphocytes from an active specific immunization patient. Delayed-type cutaneous hypersensitivity responses against a mixture of CTAA 28A32-50K and -32K were positive in seven of ten patients tested. In vitro T-cell responses upon stimulation with CTAA 28A32-32K were found to be positive in seven of ten patients and correlated with delayed-type cutaneous hypersensitivity responses to the antigen mixture. These data suggest that CTAA 28A32-32K might contain an important tumor-related T-cell epitope. Moreover, this method is suitable to define potential future candidates for antitumor vaccine development.
Assuntos
Antígenos de Neoplasias/análise , Vacina BCG/farmacologia , Neoplasias do Colo/imunologia , Neoplasias do Colo/terapia , Hipersensibilidade Tardia/imunologia , Vacinação , Animais , Anticorpos Monoclonais/imunologia , Linfócitos B/imunologia , Neoplasias do Colo/sangue , Epitopos/imunologia , Eritema/etiologia , Eritema/imunologia , Humanos , Imuno-Histoquímica , Imunoterapia , Ativação Linfocitária/imunologia , CoelhosRESUMO
111In possesses excellent radiophysical properties suitable for use in immunoscintigraphy of cancerous tissues when attached to an antitumor antibody. However, 111In has a tendency to accumulate in normal tissues such as liver. Instability of the linkage between 111In and antibody may contribute to this problem. To avoid this, we developed a new bifunctional chelating agent, 1,3-bis[N-[N-(2-aminoethyl)-2-aminoethyl]-2-aminoacetamido]-2-(4- isothiocyanatobenzyl)propane-N,N,N',N'',N''',N'''',N''''',N'''''- octaacetic acid (LiLo), that forms a kinetically stable chelate with metal ions such as indium. Using LiLo, indium-111 was conjugated to a human monoclonal antibody, 16.88. Competitive binding analysis revealed that the 16.88-LiLo conjugate is as immunoreactive as the unconjugated native antibody. This conjugate was compared with 111In-16.88, where diethylenetriaminepentaacetic acid dianhydride (DTPAa) was used as the chelating agent. In vitro stability studies showed that 111In was more stably bound to 16.88-LiLo than to 16.88-DTPA. Biodistribution studies in athymic mice bearing colorectal tumor xenografts indicated less liver retention with 16.88-LiLo than with 16.88-DTPA. These results demonstrate that LiLo is superior to DTPAa for attachment of 111In to the monoclonal antibodies.
Assuntos
Anticorpos Monoclonais , Quelantes/síntese química , Neoplasias do Colo/radioterapia , Radioisótopos de Índio/uso terapêutico , Ácido Pentético/análogos & derivados , Animais , Linhagem Celular , Linhagem Celular Transformada , Humanos , Isotipos de Imunoglobulinas , Imunoglobulina M , Indicadores e Reagentes , Radioisótopos de Índio/farmacocinética , Cinética , Camundongos , Camundongos Nus , Ácido Pentético/síntese química , Albumina Sérica/metabolismo , Distribuição Tecidual , Transplante HeterólogoRESUMO
Detection of administered human monoclonal antibodies in the tissues and circulation of patients requires special reagents to overcome interference by normal endogenous immunoglobulin. A practical approach is the development of antiidiotypic antibodies to the human monoclonal antibody and their application in immunoassays specific for the human monoclonal antibody. Accordingly, antiidiotypic antibodies were made to the monoclonal antibody 16.88, a human IgM class anti-colon carcinoma antibody being developed for applications in antibody-targeted immunotherapy of cancer. Three stable clones were obtained that produced antiidiotypic antibodies reactive with 16.88 but nonreactive with human polyclonal IgM or 16.52, a patient-matched IgM monoclonal antibody with different specificity than 16.88. One antiidiotypic antibody, MID 65, was used in a capture format radioimmunoassay to detect 16.88 in the sera of patients who had received 108-mg doses of unlabeled 16.88 coadministered with trace doses of 131I-16.88. Using this assay it was demonstrated that unlabeled 16.88 antibody and 131I-labeled 16.88 antibody did not differ significantly in blood retention for up to 24 h after administration, the period during which the immunoreactivity of the administered antibody remained over 90%. Indirect microautoradiography using exogenously applied 125I-MID 65 to localize 16.88 in frozen metastatic tumor tissue from patients given 16.88 8 days prior to surgery demonstrated the accumulation of 16.88 in areas of apparently healthy tumor cells. Much less 16.88 was detected in stroma or areas of tumor cell necrosis. The accumulation of antibody in nonnecrotic tumor sites encourages the further development of 16.88 for radioimmunotherapy of colon cancer and provides support for further development of human anticytokeratin monoclonal antibodies for cancer therapy.
Assuntos
Anticorpos Monoclonais/análise , Neoplasias do Colo/imunologia , Imunoglobulina G/análise , Animais , Anticorpos Monoclonais/sangue , Anticorpos Monoclonais/imunologia , Autorradiografia , Neoplasias do Colo/sangue , Neoplasias do Colo/secundário , Humanos , Imunoglobulina G/sangue , Imunoglobulina G/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , RadioimunoensaioRESUMO
A novel, highly water-soluble, heterobifunctional cross-linking reagent, S-(2-thiopyridyl)-L-cysteine hydrazide (TPCH), was synthesized which contains a hydrazide moiety for coupling to aldehyde groups generated in the carbohydrate residues of antibodies by mild periodate oxidation, and a pyridyl disulfide moiety for coupling to molecules with a free sulfhydryl group. Since the carbohydrate moieties are distal to the antigen binding region of antibodies, derivatization with this cross-linker minimizes impairment of the antigen binding function. Derivatization of the human monoclonal IgM antibody 16-88 against human colon carcinoma cells with as many as 16 TPCH cross-linker molecules did not impair its antigen binding capability. Using mild oxidation conditions for antibody derivatization, sialic acid residues were identified as attachment sites for the cross-linker molecules, since after desialylation of antibody 16-88 by neuraminidase virtually no cross-linker molecules could be incorporated. Comparison of TPCH with S-(2-thiopyridyl)mercaptopropionic acid hydrazide and S-(2-thiopyridyl)-L-cysteine, two related cross-linking reagents, revealed that TPCH is most efficiently incorporated into periodate-treated antibody. Based on the structural differences of the cross-linkers, the more efficient incorporation of TPCH appears to be a function of the presence of a hydrazide moiety with an adjacent amino group. When three to four molecules of pyridyl disulfide-derivatized barley toxin were coupled to TPCH-derivatized antibody 16-88, the antigen binding capability remained uncompromised. In addition, no significant impairment of toxin activity upon coupling to the antibody was observed. Based on these data, TPCH may be very useful for the synthesis of immuno-conjugates with no or only minimal impairment of the antigen binding function.
Assuntos
Carboidratos/química , Reagentes de Ligações Cruzadas/síntese química , Cisteína/análogos & derivados , Imunotoxinas/síntese química , Piridinas/síntese química , Anticorpos Monoclonais/química , Anticorpos Monoclonais/metabolismo , Neoplasias do Colo/imunologia , Reagentes de Ligações Cruzadas/química , Cisteína/síntese química , Cisteína/metabolismo , Humanos , Hidrazinas/síntese química , Hidrazinas/metabolismo , Imunotoxinas/química , Piridinas/metabolismo , Toxinas Biológicas/química , Toxinas Biológicas/metabolismoRESUMO
We studied the pharmacokinetic properties of two human monoclonal antibodies to colon carcinoma cells and their ability to detect tumors in nude mice bearing primary human colon carcinoma xenografts. The 16-88 and 28A32 monoclonal antibodies are immunoglobulin M class human antibodies produced by cell lines derived from peripheral blood lymphocytes from patients with colon carcinoma. The patients received an autologous tumor cell vaccine as part of an active specific immunotherapy protocol. The 125I-labeled antibodies were cleared from the circulation of non-tumor-bearing and tumor-bearing nude mice with a 6-8-h half-life. The half-life of the antibodies in tumor tissue was 48 to 72 h compared to 8 to 12 h for normal tissues. Tumor:normal tissue ratios were highest 4 to 7 days postinjection with tumor:blood ratios of 12:1 for 16-88 and 10:1 for 28A32 antibody. Experiments with a control human immunoglobulin M myeloma protein confirmed the specificity of the human monoclonal antibodies. Radioimmunoscintigraphic studies using nude mice bearing contralateral antibody-reactive and nonreactive colon tumor xenografts further confirmed that the antibodies specifically localized in tumor tissues. The antibody-reactive tumors were clearly visible by radioimmunoscintigraphy within 4 days of injection. These experiments, undertaken as a preliminary step to clinical trials, demonstrated for the first time that i.v. administered human immunoglobulin M monoclonal antibodies could be taken up by human colon tumor tissue and retained to a sufficient extent to easily permit tumor detection by external radioimmunoscintigraphy. These studies also demonstrated that the nude mouse human colon tumor xenograft model is a useful in vivo system for comparison studies of human monoclonal antibodies as part of a selection process for clinical trials and for evaluating immunoconjugates containing these antibodies for relative pharmacokinetic properties and potential diagnostic or therapeutic efficacy.
Assuntos
Anticorpos Monoclonais , Neoplasias do Colo/diagnóstico , Neoplasias Retais/diagnóstico , Animais , Linhagem Celular , Neoplasias do Colo/imunologia , Ensaio de Imunoadsorção Enzimática , Humanos , Imunoglobulina M , Camundongos , Camundongos Nus , Transplante de Neoplasias , Neoplasias Retais/imunologiaRESUMO
The use of human monoclonal antibodies (MCA) in the detection and treatment of human cancer has been limited by the apparent scarcity of MCA to tumor cell surface antigens. Using peripheral blood lymphocytes from autologous tumor-immunized patients, we isolated 36 MCA that react to sections of colorectal carcinoma. Twenty of these human MCA appear to be directed against cell surface antigens. Two-thirds of the human MCA-producing cell lines were diploid human B-cells rather than human-mouse heterohybridomas. Direct antibody-binding assays performed with the MCA indicated that they recognized antigenic determinants preferentially expressed on tumor cells. Experiments with paired specimens of air-dried, dissociated colon tumor cells and normal colonic mucosa cells suggested that the MCA bound significantly more to the cell surfaces of tumor cells than to the surfaces of normal colonic mucosa cells. Similarly, tests with a panel of cryostat sections of paired colon tumor and normal colonic mucosa showed that MCA bound to the tumor cells and not to the normal colonic mucosa. None of the MCA bound to cells from frozen sections of normal breast, stomach, liver, skeletal muscle, or skin. Furthermore, the human MCA did not react with carcinoembryonic antigen and human erythrocyte antigens as measured by various techniques. Our data also demonstrated that these transformed B-cells and hybridomas were stable producers of human MCA. Thus, our studies show that these tumor-specific human MCA may have the specificity and stability necessary for in vivo evaluation of their use in the detection and treatment of cancer.
Assuntos
Anticorpos Monoclonais/biossíntese , Neoplasias do Colo/imunologia , Imunização , Linfócitos/metabolismo , Neoplasias Retais/imunologia , Animais , Anticorpos Monoclonais/imunologia , Antígenos de Neoplasias/imunologia , Antígenos de Superfície/imunologia , Biotina , Antígeno Carcinoembrionário/imunologia , Linhagem Celular , Colo/imunologia , Eritrócitos/imunologia , Histocitoquímica , Humanos , Hibridomas , Mucosa Intestinal/imunologia , Leucócitos/imunologia , CamundongosRESUMO
Human lymphokine preparations can directly lyse or suppress proliferation of human tumor cells or can enhance the susceptibility of human tumor cells to lysis mediated by natural killer lymphocytes. In the past, these antitumor activities were attributed to lymphotoxin. This study demonstrates, however, that these human lymphokine antitumor cell activities are biochemically separable from lymphotoxin and are properties of a lymphokine which was named leukoregulin because it is produced by lymphocytes and it regulates target cell physiology and growth. Leukoregulin obtained by high-performance liquid chromatography and isoelectric focusing was free of detectable lymphotoxin, interferon, interleukins 1 and 2, and macrophage-activating factor activities. Leukoregulin has an apparent molecular weight of 135,000 as measured by linear gradient polyacrylamide gel electrophoresis and gel filtration chromatography and has isoelectric pHs of approximately 5.3 and 7.5. The molecular weight of leukoregulin, determined in the dissociating conditions of sodium dodecyl sulfate polyacrylamide gel electrophoresis, was 32,000. Flow cytometric analysis showed that tumor cell lysis, growth inhibition, and enhancement of susceptibility to natural killer cell-mediated cytotoxicity by leukoregulin were accompanied by rapid alterations in tumor cell membrane permeability. Lymphotoxin from human peripheral blood leukocytes and highly purified lymphotoxin from RPMI 1788 human lymphoblastoid cells lysed murine alpha-L929 tumor cells but did not possess any of the direct acting antihuman tumor cell cytostatic, cytolytic, or natural killer cell enhancing activities that leukoregulin exhibited against a broad spectrum of human tumor cell lines. The dual modes of the anticancer actions of leukoregulin, direct cytotoxicity and indirect enhancement of natural killer cell cytotoxicity, make leukoregulin a unique-acting lymphokine and suggest several ways in which leukoregulin may be used as a therapeutic agent against cancer.
Assuntos
Linfocinas/análise , Linhagem Celular , Permeabilidade da Membrana Celular , Cromatografia Líquida de Alta Pressão , Citotoxicidade Imunológica , Citometria de Fluxo , Humanos , Focalização Isoelétrica , Células Matadoras Naturais/imunologia , Linfotoxina-alfa/análise , Neoplasias/tratamento farmacológico , Neuraminidase/metabolismo , Peptídeo Hidrolases/metabolismoRESUMO
An enzyme-linked immunosorbent assay (ELISA) using a monoclonal antibody was developed to determine the clinical value of urinary fibrinogen/fibrin degradation product levels for the identification and management of patients with bladder cancer. Assays were performed on 286 serial urine specimens from 56 bladder carcinoma patients. Specimens were grouped according to whether the patient had an evident tumor at the time of specimen collection (134 specimens, 41 patients) or was clinically disease-free following treatment (152 specimens, 38 patients). Many patients contributed specimens to both groups as determined by their clinical status at the time of collection. In addition, 45 specimens from 33 patients with inflammation of the urogenital tract and 81 specimens from 19 patients with renal or prostatic cancer were assayed for urinary fibrin degradation products. The ELISA, using a high-sensitivity procedure, identified 83% of the specimens from bladder cancer-positive patients with an overall accuracy with all specimens of 78% and a false-negative rate of 5% for all specimens tested. The high-sensitivity ELISA appeared most appropriate for monitoring bladder cancer patients for recurrence of tumor after surgery. The ELISA using a high-specificity procedure appeared most appropriate for screening. The high-specificity ELISA accurately identified 96% of urine specimens from non-bladder cancer patients with a false-positive rate of only 5%. These results demonstrate that the ELISA is an efficient, reliable, quantitative, and noninvasive immunoassay that can be useful both for the identification of bladder cancer patients and for monitoring the course of the disease.
Assuntos
Fibrina/urina , Fibrinogênio/urina , Neoplasias da Bexiga Urinária/diagnóstico , Idoso , Anticorpos Monoclonais , Linhagem Celular , Membrana Celular/análise , Ensaio de Imunoadsorção Enzimática , Feminino , Fibrinogênio/análise , Humanos , Masculino , Prognóstico , Neoplasias da Bexiga Urinária/análiseRESUMO
The focus of our laboratory has been to ascertain how the poly(ADP-ribosyl)ation reaction influences the structure and biological function of nucleosomal chromatin. Antibody to poly(ADP-ribose (ADP-Rib] was coupled to Sepharose to prepare an immunoaffinity column. The following new information concerning poly(ADP-Rib) and chromatin was obtained with this column: 1) those limiting domains of nucleosomal chromatin undergoing the modification (circa 10%) could be isolated in the "bound" fraction, 2) antibody-bound nucleosomes contained all the poly ADP-ribosylated acceptors and polymerase activity of the bulk chromatin, 3) bound nucleosomes contain significant numbers of internal DNA strand breaks, and [3H]-thymidine (TdR) repair incorporation from in vivo "DNA repair label," compared to the unbound, bulk of the chromatin, 4) the presence of actively transcribed genes in "bound" nucleosomes is being investigated, 5) the acetylation modification of histones occurs in the same domains of chromatin as does poly(ADP-ribosyl)ation, and 6) poly ADP-ribosylated histone H1 can be selectively purified by the immunoaffinity method. These same histone H1 molecules appear to be equally accessible to the histone kinase, phosphorylation modification. In addition, new information has been obtained concerning histone H1 cross-linking by poly(ADP-ribosyl)ation, and on polymerase binding sites to chromatin. We have reconstituted histone H1-depleted chromatin with intact H1 and peptide domains of H1, and subsequently studied H1-poly(ADP-Rib)-complex synthesis. The data indicate that elongation of poly(ADP-Rib) proceeds on the amino terminal region of this histone. By utilizing the new techniques of DNA technology, huge advances in our understanding of the programmed structure of the eukaryotic genome have been accomplished in a relatively short time. To complement this explosion of information, it is important to ascertain how these recently appreciated properties of eukaryotic DNA are packaged within extended and condensed domains of chromatin. The research to be discussed is directed, in part, at this latter topic. We have initiated a program aimed at furthering our comprehension of chromatin structure by studying one specific, enzymatically active chromosomal protein.